台灣臨床試驗主持人資料庫|TPIDB

2016-06-01 - 2025-05-31

IIT

Phase III

Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nabpaclitaxel and carboplatin

Condition/Disease

Triple Negative Locally Advanced Breast Cancer
Test Drug

atezolizumab (MPDL3280A)

Participate Sites
7Sites

Terminated5Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

侯明鋒

Kaohsiung Municipal Gangshan Hospital

未分科

2018-01-01 - 2022-12-31

Phase III

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

Condition/Disease

HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Test Drug

Tesetaxel

Participate Sites
7Sites

Terminated7Sites

趙大中

Taipei Veterans General Hospital

陳訓徹

Linkou Chang Gung Medical Foundation

Division of General Surgery

2017-03-01 - 2019-12-31

Phase III

A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

Condition/Disease

Advanced or Metastatic Gastric Cancer
Test Drug

Apatinib

Participate Sites
10Sites

Terminated8Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源

China Medical University Hospital-Taipei

未分科

2017-06-02 - 2020-02-28

Phase III

Condition/Disease
Test Drug

Participate Sites
3Sites

Terminated3Sites

李重賓

Taipei Veterans General Hospital

Digestive System Department

2016-02-01 - 2019-05-01

Phase III

A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma

Condition/Disease

Hepatocellular Carcinoma
Test Drug

Nivolumab/Sorafenib

Participate Sites
8Sites

Terminated7Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

彭成元

China Medical University Hospital-Taipei

未分科

2016-07-01 - 2020-06-30

Phase III

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN + PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN + PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND HAVE STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Condition/Disease

NON-SMALL CELL LUNG CANCER (NSCLC)
Test Drug

Atezolizumab (MPDL3280A)

Participate Sites
10Sites

Terminated9Sites

邱昭華

Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-06-03 - 2021-02-01

Others

A Phase 1b/2 Open-label Study of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either 5-Fluorouracil or Capecitabine Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction

Condition/Disease

Adenocarcinoma of the Stomach
Test Drug

IMU-131

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-02-01 - 2025-09-30

Phase III

Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib +/- Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer 賀爾蒙受體陽性、HER2 陰性之晚期或轉移性乳癌婦女，使用 Tamoxifen 併用或不併用 Palbociclib +/- Goserelin 之亞洲跨國、多中心、隨機、雙盲、安慰劑對照第三期試驗

Condition/Disease

Advanced or Metastatic Breast Cancer
Test Drug

Ibrance / Palbociclib

Participate Sites
3Sites

Recruiting3Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2018-11-01 - 2025-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

Condition/Disease

advanced stage hepatocellular carcinoma
Test Drug

Keytruda® / Lenvima®

Participate Sites
9Sites

Terminated7Sites

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

2016-10-26 - 2020-12-31

Phase III

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, MultiCenter Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

Condition/Disease

Heart Failure With Reduced Ejection Fraction (HFrEF)
Test Drug

MK-1242 (vericiguat)

Participate Sites
6Sites

Terminated6Sites

江晨恩

Taipei Veterans General Hospital

Search Result

List